Cambridge Investment Research Advisors, Inc. Bridge Bio Pharma, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 30,802 shares of BBIO stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,802
Previous 23,805
29.39%
Holding current value
$1.42 Million
Previous $653,000
63.09%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BBIO
# of Institutions
370Shares Held
184MCall Options Held
12.8MPut Options Held
2.09M-
Viking Global Investors LP22.1MShares$1.02 Billion2.55% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY19.3MShares$890 Million30.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.9MShares$689 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$575 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.17MShares$332 Million0.14% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $6.85B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...